Skip to main content

Table 6 Blood cell counts

From: Ex vivo exposure of bone marrow from chronic kidney disease donor rats to pravastatin limits renal damage in recipient rats with chronic kidney disease

Ex vivo pravastatin pretreatment experiment recipients

Blood samples

Healthy + DMEM BMC recipients ( n = 5)

Healthy + pravastatin BMC recipients ( n = 5)

CKD + DMEM BMC recipients ( n = 10)

CKD + pravastatin BMC recipients ( n = 9)

White blood cells

5.86 ± 1.20

5.52 ± 0.93

4.63 ± 1.05

5.42 ± 1.18

Lymphocytes

3.30 ± 1.35

2.54 ± 0.29

2.60 ± 0.86

2.94 ± 0.51

Midpopulation

1.58 ± 0.29

1.56 ± 0.31

1.18 ± 0.28

1.59 ± 0.45

Granulocytes

0.98 ± 0.45

1.38 ± 0.53

0.84 ± 0.35

1.08 ± 0.52

Red blood cells

6.66 ± 0.40

6.59 ± 0.36

6.24 ± 0.59

6.63 ± 0.23

Hemoglobin

8.06 ± 0.47

7.90 ± 0.42

7.63 ± 0.72

7.86 ± 0.29

Hematocrit

0.33 ± 0.05

0.33 ± 0.019

0.31 ± 0.029

0.33 ± 0.010

Mcv

49.08 ± 0.83

50.08 ± 1.08

50.10 ± 2.09

49.35 ± 0.78

Mchc

24.38 ± 0.22

23.94 ± 0.38

24.18 ± 0.43

24.08 ± 0.36

Rdw

15.44 ± 0.43

15.22 ± 0.29

15.63 ± 1.125

15.151 ± 0.818

Platelets

736 ± 68

697 ± 49

634 ± 99

699 ± 55

Systemic in vivo pravastatin treatment

Blood samples

CKD (n = 6)

CKD + pravastatin ( n = 5)

  

White blood cells

4.81 ± 0.89

4.50 ± 1.16

  

Lymphocytes

2.87 ± 0.59

2.90 ± 0.97

  

Midpopulation

1.27 ± 0.39

0.90 ± 0.19

  

Granulocytes

0.65 ± 0.16

0.68 ± 0.13

  

Red blood cells

6.38 ± 0.22

6.25 ± 0.15

  

Hemoglobin

7.58 ± 0.32

7.52 ± 0.18

  

Hematocrit

0.32 ± 0.01

0.31 ± 0.01

  

Mcv

49.37 ± 0.79

49.96 ± 0.32

  

Mchc

24.05 ± 0.25

24.14 ± 0.23

  

Rdw

15.13 ± 0.63

15.14 ± 0.68

  

Platelets

681 ± 42

666 ± 41

  
  1. Data presented as mean ± standard deviation. BMC, bone marrow cell; CKD, chronic kidney disease; DMEM, Dulbecco’s modified Eagle medium. Mcv, Mean Corpuscular Volume; Mchc, Mean Corpuscular Hemoglobin Concentration; Rdw, Relative Distribution Width.